top of page


I'm a paragraph. Click here to add your own text and edit me. It’s easy. Just click “Edit Text” or double click me to add your own content and make changes to the font. Feel free to drag and drop me anywhere you like on your page. I’m a great place for you to tell a story and let your users know a little more about you.

This is a great space to write long text about your company and your services. You can use this space to go into a little more detail about your company. Talk about your team and what services you provide.



Due to rapid rises in sedentary lifestyle and overweight/obesity, diabetes has now reached epidemic proportions in both Mainland China and Hong Kong. A recent nationwide epidemiological survey in China showed that over 110 million adults are now suffering from diabetes and 500 million adults with prediabetes are at high risk to develop overt diabetes. 60.7% of diabetic patients currently remain undiagnosed and untreated. Diabetes is not only a major risk factor for cardiovascular disease, but is also causally associated with many types of cancers. China is projected to spend 558 billion USD as a result of diabetes and its cardiovascular complications in the next 10 years. While these chronic diseases impose an enormous social and economic burden, the huge healthcare market also represents a golden opportunity to develop our pharmaceutical and biotechnology industry in Hong Kong and Mainland China.


The State Key Laboratory of Pharmaceutical Biotechnology was approved by Chinese Ministry of Science and Technology (MOST) at July 2013, with the funding support from Hong Kong Innovation & Technology Council (ITC). Our strategic partner is State Key Laboratory of Pharmaceutical Biotechnology at Nanjing University. Our laboratory consists of a group of leading clinicians and scientists in Hong Kong across multiple disciplines, including biochemistry, molecular biology, physiology, pharmacology and pharmacy, chemistry, nanotechnology and medical engineering, to establish an integrated, open platform for basic, clinical and translational research on obesity, diabetes and its associated chronic complications. We will focus on “discovery and characterization of new hormones and biomarkers, and exploration of their potential application in the pharmaceutical and biotechnology industry”.

White Branch

About Us


Despite intensive research over the past decades, there is no cure available for diabetes and its complications. Therefore, the long-term objective of our laboratory is to develop innovative and affordable strategies for prevention and curing these chronic diseases, through vigorous basic and translational research as well as diabetes education program in our local community. Our missions are:

  • To reveal the early pathogenic pathways of obesity, diabetees and its complications;

  • To discover new biomarkers and to develop rapid assays for early diagnosis and risk predication;

  • To increase the public awareness of these chronic diseases via community-based research and education programs;

  • To provide an integrated platform for pharmaceutical and biotech industries in the Asia pacific region;

  • To become a leading research and education center for metabolic and cardiovascular medicine.

bottom of page